Overview
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company based in Italy, primarily engaged in the research and development of novel therapies for diseases of the central and peripheral nervous system. The firm's flagship product is Xadago/Safinamide, a treatment for Parkinson's disease that has been launched in multiple countries. Newron is also advancing a robust pipeline of promising projects, including Evenamide, a novel treatment for schizophrenia currently in Phase III trials, and Sarizotan, a treatment for Rett syndrome in late-stage development.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 51.39 MM.
- The operating income for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 26.17 MM.
- The net income for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 15.84 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2024-12-31 | 51.39 | 26.17 | 15.84 |
| 2024-09-30 | 29.18 | 5.58 | -1.49 |
| 2024-06-30 | 6.97 | -15.01 | -18.83 |
| 2024-03-31 | 8.01 | -13.32 | -17.53 |
| 2023-12-31 | 9.06 | -11.63 | -16.22 |
| 2023-09-30 | 8.91 | -11.39 | -16.02 |
| 2023-06-30 | 8.76 | -11.15 | -15.81 |
| 2023-03-31 | 7.43 | -12.23 | -16.65 |
| 2022-12-31 | 6.09 | -13.30 | -17.49 |
| 2022-09-30 | 6.01 | -12.11 | -15.98 |
| 2022-06-30 | 5.92 | -10.92 | -14.47 |
| 2022-03-31 | 5.84 | -11.64 | -14.69 |
| 2021-12-31 | 5.76 | -12.36 | -14.90 |
| 2021-09-30 | 5.59 | -14.17 | -17.23 |
| 2021-06-30 | 5.42 | -15.99 | -19.56 |
| 2021-03-31 | 5.34 | -17.03 | -20.28 |
| 2020-12-31 | 5.26 | -18.07 | -21.00 |
| 2020-09-30 | 6.29 | -17.25 | -18.83 |
Income Statement: EPS
- The earnings per share basic for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 0.85.
- The earnings per share diluted for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 0.77.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2024-12-31 | 0.85 | 0.77 |
| 2024-09-30 | -0.08 | -0.08 |
| 2024-06-30 | -1.03 | -1.03 |
| 2024-03-31 | -0.97 | -0.97 |
| 2023-12-31 | -0.91 | |
| 2023-09-30 | -0.90 | -0.90 |
| 2023-06-30 | -0.89 | -0.89 |
| 2023-03-31 | -0.93 | -0.93 |
| 2022-12-31 | -0.98 | |
| 2022-09-30 | -0.90 | -0.90 |
| 2022-06-30 | -0.81 | -0.81 |
| 2022-03-31 | -0.82 | -0.82 |
| 2021-12-31 | -0.84 | |
| 2021-09-30 | -0.97 | -0.97 |
| 2021-06-30 | -1.10 | -1.10 |
| 2021-03-31 | -1.14 | -1.14 |
| 2020-12-31 | -1.18 | |
| 2020-09-30 | -1.06 | -1.06 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is -17.61 MM.
- The cash from investing activities for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 3.16 MM.
- The cash from financing activities for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 15.05 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2024-12-31 | -17.61 | 3.16 | 15.05 |
| 2024-09-30 | -15.49 | 4.21 | 11.67 |
| 2024-06-30 | -13.37 | 5.27 | 8.28 |
| 2024-03-31 | -11.75 | 4.26 | 4.05 |
| 2023-12-31 | -10.14 | 3.25 | -0.19 |
| 2023-09-30 | -10.60 | 1.67 | -0.19 |
| 2023-06-30 | -11.06 | 0.09 | -0.19 |
| 2023-03-31 | -11.08 | -0.12 | -0.19 |
| 2022-12-31 | -11.09 | -0.32 | -0.19 |
| 2022-09-30 | -9.71 | 0.32 | 7.32 |
| 2022-06-30 | -8.32 | 0.96 | 14.82 |
| 2022-03-31 | -9.88 | 4.69 | 14.82 |
| 2021-12-31 | -11.45 | 8.42 | 14.83 |
| 2021-09-30 | -14.37 | 7.72 | 7.34 |
| 2021-06-30 | -17.30 | 7.03 | -0.16 |
| 2021-03-31 | -16.44 | 3.21 | 3.60 |
| 2020-12-31 | -15.59 | -0.62 | 7.37 |
| 2020-09-30 | -14.95 | -0.77 | 16.11 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 |
Management Effectiveness
- The roa for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is -0.73.
- The roic for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is -1.05.
- The croic for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 0.01.
- The ocroic for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is -0.74.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2024-12-31 | -0.73 | -1.05 | 0.01 | -0.74 | |
| 2024-09-30 | -0.73 | -1.05 | 0.01 | -0.74 | |
| 2024-06-30 | -0.52 | -0.88 | -0.38 | -0.55 | |
| 2024-03-31 | -0.44 | -0.88 | -0.38 | -0.55 | |
| 2023-12-31 | -0.42 | -0.61 | -0.35 | -0.41 | |
| 2023-09-30 | -0.36 | -0.61 | -0.43 | -0.42 | |
| 2023-06-30 | -0.40 | -0.64 | -0.45 | -0.45 | |
| 2023-03-31 | -0.40 | -0.68 | -0.46 | -0.45 | |
| 2022-12-31 | -0.35 | -5.63 | -0.55 | -0.37 | -0.35 |
| 2022-09-30 | -0.29 | -5.14 | -0.53 | -0.07 | -0.32 |
| 2022-06-30 | -0.37 | -1.67 | -0.38 | 0.20 | -0.22 |
| 2022-03-31 | -0.37 | -1.69 | -0.39 | 0.25 | -0.26 |
| 2021-12-31 | -0.38 | -0.86 | -0.50 | 0.39 | -0.48 |
| 2021-09-30 | -0.34 | -1.00 | -0.57 | 0.02 | -0.48 |
| 2021-06-30 | -0.34 | -0.72 | -0.55 | -0.29 | -0.48 |
| 2021-03-31 | -0.35 | -0.75 | -0.57 | -0.27 | -0.46 |
| 2020-12-31 | -0.35 | -0.57 | -0.48 | -0.20 | -0.36 |
| 2020-09-30 | -0.31 | -0.51 | -0.43 | 0.01 | -0.34 |
Gross Margins
- The gross margin for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is 1.00.
- The net margin for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is -2.70.
- The operating margin for Newron Pharmaceuticals S.p.A. as of 31 December 2024 is -2.15.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2024-12-31 | 1.00 | -2.70 | -2.15 |
| 2024-09-30 | 1.00 | -2.70 | -2.15 |
| 2024-06-30 | 1.00 | -1.79 | -1.28 |
| 2024-03-31 | 1.00 | -1.79 | -1.28 |
| 2023-12-31 | 1.00 | -1.80 | -1.27 |
| 2023-09-30 | 1.00 | -1.80 | -1.27 |
| 2023-06-30 | 1.00 | -1.80 | -1.27 |
| 2023-03-31 | 1.00 | -2.24 | -1.65 |
| 2022-12-31 | 1.00 | -2.87 | -2.18 |
| 2022-09-30 | 1.00 | -2.66 | -2.02 |
| 2022-06-30 | 1.00 | -2.44 | -1.84 |
| 2022-03-31 | 1.00 | -2.51 | -1.99 |
| 2021-12-31 | 1.00 | -2.59 | -2.14 |
| 2021-09-30 | 1.00 | -3.08 | -2.53 |
| 2021-06-30 | 1.00 | -3.61 | -2.95 |
| 2021-03-31 | 1.00 | -3.80 | -3.19 |
| 2020-12-31 | 1.00 | -3.99 | -3.44 |
| 2020-09-30 | 1.00 | -3.00 | -2.74 |
Identifiers and Descriptors
| Central Index Key (CIK) |
